In Japan, it is quite rare for an investigator to submit an investigational new drug application to initiate a clinical trial and obtain approval of a drug on the basis of clinical trial results. This means that development of new therapies is currently driven almost entirely by pharmaceutical companies as opposed to independent investigators. Here, we provide our perspective on the reasons for this situation and advocate investigator-initiated cancer drug development as a means of increasing access to better therapies for Japanese cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) Guidance for Industry: IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer [online], (2004).
Fujiwara, Y. Future perspectives of registration-directed clinical trials from the standpoint of large academic hospital [Japanese]. Farumashia 44, 789–794 (2008).
UMIN Clinical Trials Registry [online], (2009).
JMACCT Clinical Trial Information Registration [online], (2009).
US Department of Health and Human Services, Food and Drug Administration, Office of Regulatory Affairs: Guidance for Industry: Guideline for the Monitoring of Clinical Investigations [online], (1998).
American Society of Clinical Oncology. Reimbursement for cancer treatment: Coverage of off-label drug indications. J. Clin. Oncol. 19, 3206–3208 (2006).
Tsuji, K. & Tsutani, K. Follow the leader. Nature 453, 851–852 (2008).
Trimble, E. L. et al. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J. Clin. Oncol. 27, 5109–5114 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Imamura, C., Takebe, N., Nakamura, S. et al. Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol 7, 127–128 (2010). https://doi.org/10.1038/nrclinonc.2010.13
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.13